02
BEFORE / AFTER

What changed from existing technology?

Existing technology

This study shows a fast way to test personalized nucleic acid therapies in heart organoids made from patient cells.

This research

The method enables rapid and scalable screening of personalized ASO therapies in patient-derived organoids, which was not previously feasible.

03 · REALITY CHECK

Current stage: Prototype

Classified from the research published in Nature and its publicly reported validation. Manufacturing and revenue evidence require separate confirmation.

Current stagePrototype
Basic researchExperimental validationPrototypeField validationNear commercialization
04
REMAINING CHALLENGES

What still needs to be solved?

Follow-up validation points are being checked.

Solving these issues would increase the chance of reaching products and industry use.

05
INDUSTRY OPPORTUNITY

What could change if this succeeds?

Follow the path from technology to materials, components, equipment, and services.

01Basic research

Identify disease mechanisms and therapeutic targets

02Diagnostics and therapeutics

Turn research findings into diagnostic methods and treatment candidates

03Preclinical and clinical validation

Evaluate safety and efficacy before and during use in people

04Biomanufacturing

Repeatedly manufacture therapies and diagnostic products

06 · ONE MORE POSSIBILITYOne possibility beyond the paper

This approach could be used to accelerate the development of personalized nucleic acid therapies for heart diseases.

08 · EVIDENCE & SOURCES

Evidence and sources

View paper and company evidenceKey paperRapid and scalable personalized ASO screening in patient-derived organoidsNature · 2025.01.22 ↗
KEEP EXPLORING

Related technology in this field